3D printing of biologics-what has been accomplished to date?
Drug Discov Today. 2023 Nov 8:103823. doi: 10.1016/j.drudis.2023.103823. Online ahead of print.ABSTRACTThree-dimensional (3D) printing is a promising approach for the stabilization and delivery of non-living biologics. This versatile tool builds complex structures and customized resolutions, and has significant potential in various industries, especially pharmaceutics. Biologics have become increasingly prevalent in the field of medicine due to their diverse applications and benefits. Stability is the main attribute that must be achieved during the development of biologic formulations. 3D printing could help to stabilize b...
Source: Drug Discovery Today - November 10, 2023 Category: Drugs & Pharmacology Authors: Anqi Lu Robert O Williams Mohammed Maniruzzaman Source Type: research

Molecular basis of phytochemical-gut microbiota interactions
Drug Discov Today. 2023 Nov 8:103824. doi: 10.1016/j.drudis.2023.103824. Online ahead of print.ABSTRACTDysbiosis-associated molecular pathology is significantly involved in developing and perpetuating metabolic disorders, disrupting host energy regulation, and triggering inflammatory signaling cascades, insulin resistance, and metabolic dysfunction. Concurrently, numerous phytoconstituents are able to interact with the gut microbiota and produce bioactive metabolites that influence host cellular pathways, inflammation, and metabolic processes. These effects include improved insulin sensitivity, lipid metabolism regulation,...
Source: Drug Discovery Today - November 10, 2023 Category: Drugs & Pharmacology Authors: Samridhi Lal Md Sayeed Akhtar Mohd Faiyaz Khan Saad A Aldosari Monalisa Mukherjee Arun K Sharma Source Type: research

Bioinspired theranostic quantum dots: paving the road to a new paradigm for cancer diagnosis and therapeutics
Drug Discov Today. 2023 Nov 8:103822. doi: 10.1016/j.drudis.2023.103822. Online ahead of print.ABSTRACTDespite extensive research, a complete cure remains lacking for most types of cancer. Nanotechnology-based carriers, such as liposomes, nanoparticles (NPs), dendrimers, nanoemulsions, and other nanocarriers, can target cancer cells, but their in vivo fate is unpredictable. Bioinspired quantum dots (BQDs) offer enhanced aqueous solubility, exceptionally low toxicity, biocompatibility, easy biofunctionalization, and selective cancer targeting. Given their photoluminescence, high longitudinal relaxation value, photothermal e...
Source: Drug Discovery Today - November 10, 2023 Category: Drugs & Pharmacology Authors: Farhan Mazahir Rajeev Sharma Awesh Kumar Yadav Source Type: research

Unravelling the potential of mitochondria-targeted liposomes for enhanced cancer treatment
Drug Discov Today. 2023 Nov 6:103819. doi: 10.1016/j.drudis.2023.103819. Online ahead of print.ABSTRACTMitochondria are the primary organelles of cells involved in various physiochemical and biochemical processes. Owing to their crucial role in cellular metabolism, mitochondria are favored therapeutic targets for the treatment and prevention of cancers. Recently, there has been growing interest in the use of mitochondria-specific functional nanoparticles for targeted delivery of therapeutic agents to these organelles. Among several nanosystems, liposomes have garnered considerable attention owing to their exceptional drug ...
Source: Drug Discovery Today - November 8, 2023 Category: Drugs & Pharmacology Authors: Mohammad Sameer Khan B H Jaswanth Gowda Waleed H Almalki Tanuja Singh Amirhossein Sahebkar Prashant Kesharwani Source Type: research

Unravelling the potential of mitochondria-targeted liposomes for enhanced cancer treatment
Drug Discov Today. 2023 Nov 6:103819. doi: 10.1016/j.drudis.2023.103819. Online ahead of print.ABSTRACTMitochondria are the primary organelles of cells involved in various physiochemical and biochemical processes. Owing to their crucial role in cellular metabolism, mitochondria are favored therapeutic targets for the treatment and prevention of cancers. Recently, there has been growing interest in the use of mitochondria-specific functional nanoparticles for targeted delivery of therapeutic agents to these organelles. Among several nanosystems, liposomes have garnered considerable attention owing to their exceptional drug ...
Source: Drug Discovery Today - November 8, 2023 Category: Drugs & Pharmacology Authors: Mohammad Sameer Khan B H Jaswanth Gowda Waleed H Almalki Tanuja Singh Amirhossein Sahebkar Prashant Kesharwani Source Type: research

Unravelling the potential of mitochondria-targeted liposomes for enhanced cancer treatment
Drug Discov Today. 2023 Nov 6:103819. doi: 10.1016/j.drudis.2023.103819. Online ahead of print.ABSTRACTMitochondria are the primary organelles of cells involved in various physiochemical and biochemical processes. Owing to their crucial role in cellular metabolism, mitochondria are favored therapeutic targets for the treatment and prevention of cancers. Recently, there has been growing interest in the use of mitochondria-specific functional nanoparticles for targeted delivery of therapeutic agents to these organelles. Among several nanosystems, liposomes have garnered considerable attention owing to their exceptional drug ...
Source: Drug Discovery Today - November 8, 2023 Category: Drugs & Pharmacology Authors: Mohammad Sameer Khan B H Jaswanth Gowda Waleed H Almalki Tanuja Singh Amirhossein Sahebkar Prashant Kesharwani Source Type: research

Polycystic ovarian syndrome: Current scenario and future insights
Drug Discov Today. 2023 Nov 5:103821. doi: 10.1016/j.drudis.2023.103821. Online ahead of print.ABSTRACTPolycystic ovarian syndrome (PCOS) prevails in approximately 33% of females of reproductive age globally. Although the root cause of the disease is unknown, attempts are made to clinically manage the disturbed hormone levels and symptoms arising due to hyperandrogenism, a hallmark of PCOS. This review presents detailed insights on the etiology, risk factors, current treatment strategies, and challenges therein. Medicinal agents currently in clinical trials and those in the development pipeline are emphasized. The signific...
Source: Drug Discovery Today - November 7, 2023 Category: Drugs & Pharmacology Authors: Swanand Kulkarni Khushi Gupta Pooja Ratre Pradyumna Kumar Mishra Yogesh Singh Avadh Biharee Suresh Thareja Source Type: research

Privacy-preserving techniques for decentralized and secure machine learning in drug discovery
Drug Discov Today. 2023 Nov 5:103820. doi: 10.1016/j.drudis.2023.103820. Online ahead of print.ABSTRACTData availability, data security, and privacy concerns often hamper optimal performance efficiency of machine learning (ML) techniques. Therefore, novel techniques for the utilization of private/sensitive data in the field of drug discovery have been proposed for ML model-building tasks. Some examples of the different techniques are secure multiparty computation, distributed deep learning, homomorphic encryption, blockchain-based peer-to-peer networking, differential privacy, and federated learning, as well as combination...
Source: Drug Discovery Today - November 7, 2023 Category: Drugs & Pharmacology Authors: Aljo ša Smajić Melanie Grandits Gerhard F Ecker Source Type: research

Psychedelic renaissance: revitalized potential therapies for psychiatric disorders
Drug Discov Today. 2023 Nov 2:103818. doi: 10.1016/j.drudis.2023.103818. Online ahead of print.ABSTRACTPsychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic agents for psychiatric disorders has recently re-emerged. Here, we review progress in the development of psychedelic compounds that have potential therapeutic effects as well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and the entactogen 3,4-methyl-enedioxy-methamphetamine (MDMA). We also review the potential inte...
Source: Drug Discovery Today - November 4, 2023 Category: Drugs & Pharmacology Authors: Taeho Greg Rhee Pasha A Davoudian Gerard Sanacora Samuel T Wilkinson Source Type: research

Psychedelic renaissance: revitalized potential therapies for psychiatric disorders
Drug Discov Today. 2023 Nov 2:103818. doi: 10.1016/j.drudis.2023.103818. Online ahead of print.ABSTRACTPsychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic agents for psychiatric disorders has recently re-emerged. Here, we review progress in the development of psychedelic compounds that have potential therapeutic effects as well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and the entactogen 3,4-methyl-enedioxy-methamphetamine (MDMA). We also review the potential inte...
Source: Drug Discovery Today - November 4, 2023 Category: Drugs & Pharmacology Authors: Taeho Greg Rhee Pasha A Davoudian Gerard Sanacora Samuel T Wilkinson Source Type: research

Psychedelic renaissance: revitalized potential therapies for psychiatric disorders
Drug Discov Today. 2023 Nov 2:103818. doi: 10.1016/j.drudis.2023.103818. Online ahead of print.ABSTRACTPsychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic agents for psychiatric disorders has recently re-emerged. Here, we review progress in the development of psychedelic compounds that have potential therapeutic effects as well as the safety concerns. We include psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and the entactogen 3,4-methyl-enedioxy-methamphetamine (MDMA). We also review the potential inte...
Source: Drug Discovery Today - November 4, 2023 Category: Drugs & Pharmacology Authors: Taeho Greg Rhee Pasha A Davoudian Gerard Sanacora Samuel T Wilkinson Source Type: research

Micro- and nanoformulations of antibiotics against Brucella
Drug Discov Today. 2023 Nov 1:103809. doi: 10.1016/j.drudis.2023.103809. Online ahead of print.ABSTRACTBrucellosis, a zoonotic intracellular bacterial infection primarily transmitted through the consumption of unpasteurized milk from infected animals, remains a challenging condition to clinically control. This is mainly because of the limited effectiveness of conventional antibiotics in targeting intracellular Brucella. Micro- and nanoformulations of antibiotics, whether used as a mono- or combination therapy, have the potential to reduce the antibiotic doses required and treatment duration. Extensive research has been con...
Source: Drug Discovery Today - November 3, 2023 Category: Drugs & Pharmacology Authors: Mehran Alavi Ali Nokhodchi Source Type: research

Evaluating the impact of the FDA's orphan drug designation on share prices of biotechnology companies
Drug Discov Today. 2023 Oct 26:103807. doi: 10.1016/j.drudis.2023.103807. Online ahead of print.ABSTRACTThis analysis explores the impact of the FDA's orphan drug designation (ODD) on biotechnology companies' share prices in the short and long term. Our analysis reveals that there is a significant immediate increase in share prices following an ODD announcement, which underscores its potential as a robust indicator of short-term investor returns. However, the long-term findings present a more complex picture, with a sustained impact within the biotech industry but a significant depreciation against the broader market over ...
Source: Drug Discovery Today - October 28, 2023 Category: Drugs & Pharmacology Authors: Joab Williamson Alexander James Spicer Source Type: research

Evaluating the impact of the FDA's orphan drug designation on share prices of biotechnology companies
Drug Discov Today. 2023 Oct 26:103807. doi: 10.1016/j.drudis.2023.103807. Online ahead of print.ABSTRACTThis analysis explores the impact of the FDA's orphan drug designation (ODD) on biotechnology companies' share prices in the short and long term. Our analysis reveals that there is a significant immediate increase in share prices following an ODD announcement, which underscores its potential as a robust indicator of short-term investor returns. However, the long-term findings present a more complex picture, with a sustained impact within the biotech industry but a significant depreciation against the broader market over ...
Source: Drug Discovery Today - October 28, 2023 Category: Drugs & Pharmacology Authors: Joab Williamson Alexander James Spicer Source Type: research

Evaluating the impact of the FDA's orphan drug designation on share prices of biotechnology companies
Drug Discov Today. 2023 Oct 26:103807. doi: 10.1016/j.drudis.2023.103807. Online ahead of print.ABSTRACTThis analysis explores the impact of the FDA's orphan drug designation (ODD) on biotechnology companies' share prices in the short and long term. Our analysis reveals that there is a significant immediate increase in share prices following an ODD announcement, which underscores its potential as a robust indicator of short-term investor returns. However, the long-term findings present a more complex picture, with a sustained impact within the biotech industry but a significant depreciation against the broader market over ...
Source: Drug Discovery Today - October 28, 2023 Category: Drugs & Pharmacology Authors: Joab Williamson Alexander James Spicer Source Type: research